Bellicum Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
Jefferies Raises Price Target on Bellicum Pharma (BLCM) to $22; Reiterates Buy
August 9, 2016 9:50 AM EDTJefferies reiterated a Buy rating on Bellicum Pharmaceuticals (NASDAQ: BLCM), and raised the price target to $22.00 (from $20.00), following the company's 2Q earnings report. BLCM reported a Q2 GAAP EPS of ($0.61) vs. estimates of ($0.59).
Analyst Biren Amin commented, "BLCM reported 2Q financial results... More
Bellicum Pharma (BLCM) Misses Q2 EPS by 4c
August 8, 2016 5:06 PM EDTBellicum Pharma (NASDAQ: BLCM) reported Q2 EPS of ($0.61), $0.04 worse than the analyst estimate of ($0.57).
For earnings history and earnings-related data on Bellicum Pharma (BLCM) click here.
... More